Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Дифференциальный диагноз и лечение первичного рака брюшины и мезотелиомы (литературный обзор)
Дифференциальный диагноз и лечение первичного рака брюшины и мезотелиомы (литературный обзор)
Абдуллаев А.Г., Козлов П.А., Шахпазян Н.К., Цыганкова А.В. Дифференциальный диагноз и лечение первичного рака брюшины и мезотелиомы (литературный обзор). Современная Онкология. 2020; 22 (4): 91–95. DOI: 10.26442/18151434.2020.4.200271
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Первичный рак брюшины и мезотелиома относятся к одной нозологической структуре – первичные злокачественные новообразования брюшины. Данные патологии, несмотря на их морфологические различия, объединяют низкая заболеваемость, отсутствие патогмоничных симптомов, схожесть радиологических признаков и недостаточная изученность прогностических факторов. Учитывая низкую заболеваемость, в настоящее время не установлены надежные дифференциально-диагностические признаки, что в значительной степени затрудняет своевременную формулировку диагноза. Напротив, все чаще выявляются случаи выбора неправильной тактики лечения, отсутствия унифицированного алгоритма ведения, когда, по сути, история болезни каждого пациента представляет собой индивидуальное «творчество» того или иного врача. С другой стороны, самостоятельный опыт многих клиник не превышает нескольких наблюдений, что не позволяет врачам уверенно ориентироваться в проблеме. Соответственно, назрела необходимость проведения многоцентровых и, возможно, проспективных рандомизированных научных исследований с целью выработки единого алгоритма ведения больных с первичными новообразованиями брюшины. Традиционные алгоритмы лечения данной патологии включают хирургический этап и системную или внутриполостную химиотерапию, при этом последовательность лечения может быть разной и зависит в первую очередь от распространенности болезни. В настоящее время с целью определения степени интраперитонеальной диссеминации используется индекс перитонеального канцероматоза, предложенный P. Sugabaker. Также доказано, что одним из основных прогностических факторов является степень полноты циторедукции. В данной статье мы постарались представить современные данные о диагностике, лечении и прогнозе при первичном раке брюшины и мезотелиоме брюшины.
Ключевые слова: первичные новообразования брюшины, первичный рак брюшины, мезотелиома брюшины.
Key words: primary neoplasms of the peritoneum, primary cancer of the peritoneum, peritoneal mesothelioma.
Ключевые слова: первичные новообразования брюшины, первичный рак брюшины, мезотелиома брюшины.
________________________________________________
Key words: primary neoplasms of the peritoneum, primary cancer of the peritoneum, peritoneal mesothelioma.
Полный текст
Список литературы
1. Tan GH, Cheung M, Soo KC, Teo MC. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore 2013; 42 (6): 291–6.
2. Park MS, Araujo DM. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol 2009; 21 (4): 327–31. DOI: 10.1097/CCO.0b013e32832c9532
3. Benhammane H, Chbani L, Ousadden A et al. Desmoplastic small round cell tumor of the abdomen: A case report and literature review of therapeutic options. Health 2012; 4 (4): 207–11.
4. Li G, Zhang Z, Ma X et al. Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. PLoS One 2013; 8 (1): E.54233. DOI: 10.1371/journal. pone.0054233
5. Sugarbaker PH. Cytoreduction including total gastrectomy for pseudomyxoma peritonei. Brit J Surg 2002; 89: 208–12.
6. Barnetson RJ, Burnett RA, Downie I et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 2006; 125 (1): 67–76.
7. Deraco M, Santoro N, Carraro O et al. Peritoneal carcinomatosis: feature of dissemination. A review. Tumori 1999; 85: 1–5.
8. Смирнова Г.Ф., Кириченко А.Д., Фетисова Т.И. и др. Редкий случай диссеминированного перитонеального лейомиоматоза. Сиб. онкологический журн. 2010; 1: 85–7.
[Smirnova G.F., Kirichenko A.D., Fetisova T.I. et al. Rare case of disseminated peritoneal leiomyomatosis. Siberian Journal of Oncology. 2010; 1: 85–7 (in Russian).]
9. Japanese Classification of Gastric Carcinoma. 2nd English Edition Gastric Cancer. Gastric Cancer 1998; 1: 10–24.
10. Абдуллаев А.Г. Современная система диагностики и лечения псевдомиксомы и мезотелиомы брюшины. Автореф. дис. … д-ра мед. наук. М., 2016.
[Abdullaev A.G. Modern system of diagnostics and treatment of pseudomyxoma and peritoneal mesothelioma. Authoref. dis. ... d-ra med. nauk. Moscow, 2016 (in Russian).]
11. Mok SC, Schorge JO, Weich WR et al. Peritoneal tumours. In: World Health Organization Classifi cation of tumours. Pathology & genetics of tumours of breast and female genital organs. IARC Press – Lyon, 2003; p. 197–202.
12. Shmueli E, Leider-Trejo L, Schwartz I et al. Primary papillary serous carcinoma of the peritoneum in a man. Ann Oncol 2001; 12: 563–7.
13. Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal and fallopian tube carcinomas in the United States, 1995–2004. Cancer Epidemiol Biomarkers Prev 2009; 18: 132–9.
14. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005; 123 (5): 724–37.
15. Eltabbakh GH, Piver MS. Oncology. 12nd ed. Washington: Williston Park, 1998; p. 813–19.
16. De Panther Manzini V. Malignant peritoneal mesothelioma. Tumori 2005; 91: 1–5.
17. Tejido Garcia R, Anta Fernandez M, Hernandez Hernandez JL et al. Fever of unknown origin as the clinical presentation of malignant peritoneal mesothelioma. Ann Med Interna 1997; 14: 573–5 (in Spanish).
18. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005; 123: 724–37.
19. Le DT, Deavers M, Hunt K et al. Cisplatin and irinotecan (CPT – 11) for peritoneal mesothelioma. Cancer Invest 2003; 21: 682–9.
20. Naka H, Naka A. Clinicopathological study on 100 Japanese patients with peritoneal mesothelioma in Japan. Gan No Rinsho 1984; 30: 1–10.
21. Schneiderman H. Mesothelioma and venous thrombosis. CMAJ 2004 ; 171: 11.
22. Bahrami A, Luan DT, Jae YR. Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med 2008; 132 (3): 326–48.
23. WHO Classification of Tumors of female reproductive organs, 2014.
24. Whittemore AS, Gong G, John EM et al. Prevalence of BRCA1 mutations carriers among non-Hispanic Whites. Cancer Epidemiol Biomarkers 2004; 13: 2078–83.
25. Piver MS, Baker TR, Jishi MF et al. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer 1993; 71: 582–8.
26. Schorge JO, Muto MG, Lee SJ et al. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 2000; 60: 1361–4.
27. Sridhar K, Doria R, Raub W et al. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992; 70 (12): 2969–79.
28. Van Gelder T, Hoogsteden H, Versnel M et al. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989; 43 (4): 222–7.
29. Абдуллаев А.Г., Полоцкий Б.Е., Давыдов М.М. Показатели уровней опухолевых маркеров при псевдомиксоме и мезотелиоме брюшины. Онкогинекология. 2016; 1: 31–6.
[Abdullaev A.G., Polotskiy B.E., Davydov M.M. The levels of tumor markers for pseudomyxoma and peritoneal mesothelioma. Oncogynecology. 2016; 1: 31–6 (in Russian).]
30. Antmann KH, Pomfret EA, Aisner J et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1983; 1 (6): 386–99.
31. Antman K, Shemin R, Ryan L et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988; 6: 147–53.
32. Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32: 676–81.
33. Piccigallo E, Jeffers L, Reddy R et al. Malignant peritoneal mesothelioma. A clinical and laparoscopic study of ten cases. Dig Dis Sci 1988; 33 (5): 633–9.
34. Turner K, Varghese S, Alexander HR Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 2012; 10: (1): 49–57.
35. Langer CJ, Rosenblum N, Hogan M et al. Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: Favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 1993; 32: 204–8.
36. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118 (7): 547–50.
37. Manzini V, Recchia L, Cafferata M et al. Malignant peritoneal mesothelioma: A multicenter study on 81 cases. Ann Oncol 2010; 21 (2): 348–53.
38. Blackham AU, Shen P, Stewart JH et al. Cytoreductive surgery with intraperitoneal chemotherapy for malignant peritoneal mesothelioma: mitomycin vs. cisplatin. Ann Surg Oncol 2010; 17: 2720–7.
39. Yan TD, Deraco M, Baratti D et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. J Clin Oncol 2009; 27 (36): 6237–42.
40. Helm JH, Miura JT, Glenn JA et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis. Ann Surg Oncol 2015; 22 (5): 1686–93. DOI: 10.1245/s10434-014-3978-x
41. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248–59.
42. Тюляндина А.С., Румянцев А.А., Морхов К.Ю. и др. Ретроспективный анализ отдаленных результатов применения первичной циторедукции и предоперационной химиотерапии на первом этапе лечения больных IIIC–IV стадий рака яичника. Злокачественные опухоли. 2018; 8 (3): 86–94. DOI: 10.18027/2224-5057-2018-8-3-86-94
[Tjulandin A.S., Rumyantsev A.A., Morkhov K.Y. et al. Retrospective analysis of long-term survival outcomes of primary cytoreduction and neoadjuvant chemotherapy in patients with ovarian cancer stage IIIC–IV. Malignant Tumours. 2018; 3: 86–94. DOI: 10.18027/2224-5057-2018-8-3-86-94 (In Russian).]
43. Gourley C, Walker JL, Mackay HJ. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book 2016; 35: 143–51.
44. Vergote I, Trope CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943–53.
45. Chi DS, Musa F, Dao F et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012; 124: 10–4.
46. Комов Д.В., Колядина И.В., Поликарпова С.Б. и др. Сложности диагностики рака червеобразного отростка: клиническое наблюдение. Рос. онкологический журн. 2013; 2: 40–2.
[Komov D.V., Kolyadina I.V., Polikarpova S.B. et al. Difficulties in the diagnosis of appendix cancer: a clinical report. Russian Journal of Oncology. 2013; 2: 40–2 (in Russian).]
47. Колядина И.В., Комов Д.В., Рощин Е.М. и др. Метастатическое поражение мягких тканей передней брюшной стенки (описание клинического случая). Современная онкология. 2009; 11 (1): 54–7.
[Kolyadina I.V., Komov D.V., Roshchin E.M. et al. Metastatic lesion of the soft tissues of the anterior abdominal wall (description of the clinical case). Journal of Modern Oncology. 2009; 11 (1): 54–7 (in Russian).]
48. Филоненко Д.А., Ганьшина И.П., Кондратьева О.Е. и др. Особенности метастазирования долькового рака молочной железы. Акушерство и гинекология. 2019; 10: 180–7.
[Filonenko D.A., Ganshina I.P., Kondratyeva O.E. et al. Characteristics of metastatic lobular breast cancer. Obstetrics and Gynecology. 2019; 10: 180–7 (in Russian).]. DOI: 10.18565/aig.2019.10.180-187
49. Колядина И.В., Абдуллаев А.Г., Танишина Н.Б. и др. Мультимодальный подход к дифференциальной диагностике метастатического поражения при раке молочной железы: описание клинического случая. Злокачественные опухоли. 2017; 3: 31–6. DOI: 10.18027/2224-5057-2017-3-31-36
[Kolyadina I.V., Abdullaev A.G., Tanishina N.B. et al. Multimodal approach to differential diagnosis of breast cancer metastatic lesions: case report. Malignant Tumours. 2017; 3: 31–6. DOI: 10.18027/2224-5057-2017-3-31-36 (In Russian).]
50. Колядина И.В., Ганьшина И.П., Жукова Л.Г. и др. Метастатическое поражение мягких тканей ягодичной области при HER2+ раке молочной железы: описание клинического случая. Современная онкология. 2017; 19 (4): 36–8.
[Kolyadina I.V., Ganshina I.P., Zhukova L.G. et al. Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case. Journal of Modern Oncology. 2017; 19 (4): 36–8 (In Russian).]
2. Park MS, Araujo DM. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol 2009; 21 (4): 327–31. DOI: 10.1097/CCO.0b013e32832c9532
3. Benhammane H, Chbani L, Ousadden A et al. Desmoplastic small round cell tumor of the abdomen: A case report and literature review of therapeutic options. Health 2012; 4 (4): 207–11.
4. Li G, Zhang Z, Ma X et al. Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. PLoS One 2013; 8 (1): E.54233. DOI: 10.1371/journal. pone.0054233
5. Sugarbaker PH. Cytoreduction including total gastrectomy for pseudomyxoma peritonei. Brit J Surg 2002; 89: 208–12.
6. Barnetson RJ, Burnett RA, Downie I et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 2006; 125 (1): 67–76.
7. Deraco M, Santoro N, Carraro O et al. Peritoneal carcinomatosis: feature of dissemination. A review. Tumori 1999; 85: 1–5.
8. Smirnova G.F., Kirichenko A.D., Fetisova T.I. et al. Rare case of disseminated peritoneal leiomyomatosis. Siberian Journal of Oncology. 2010; 1: 85–7 (in Russian).
9. Japanese Classification of Gastric Carcinoma. 2nd English Edition Gastric Cancer. Gastric Cancer 1998; 1: 10–24.
10. Abdullaev A.G. Modern system of diagnostics and treatment of pseudomyxoma and peritoneal mesothelioma. Authoref. dis. ... d-ra med. nauk. Moscow, 2016 (in Russian).
11. Mok SC, Schorge JO, Weich WR et al. Peritoneal tumours. In: World Health Organization Classifi cation of tumours. Pathology & genetics of tumours of breast and female genital organs. IARC Press – Lyon, 2003; p. 197–202.
12. Shmueli E, Leider-Trejo L, Schwartz I et al. Primary papillary serous carcinoma of the peritoneum in a man. Ann Oncol 2001; 12: 563–7.
13. Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal and fallopian tube carcinomas in the United States, 1995–2004. Cancer Epidemiol Biomarkers Prev 2009; 18: 132–9.
14. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005; 123 (5): 724–37.
15. Eltabbakh GH, Piver MS. Oncology. 12nd ed. Washington: Williston Park, 1998; p. 813–19.
16. De Panther Manzini V. Malignant peritoneal mesothelioma. Tumori 2005; 91: 1–5.
17. Tejido Garcia R, Anta Fernandez M, Hernandez Hernandez JL et al. Fever of unknown origin as the clinical presentation of malignant peritoneal mesothelioma. Ann Med Interna 1997; 14: 573–5 (in Spanish).
18. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005; 123: 724–37.
19. Le DT, Deavers M, Hunt K et al. Cisplatin and irinotecan (CPT – 11) for peritoneal mesothelioma. Cancer Invest 2003; 21: 682–9.
20. Naka H, Naka A. Clinicopathological study on 100 Japanese patients with peritoneal mesothelioma in Japan. Gan No Rinsho 1984; 30: 1–10.
21. Schneiderman H. Mesothelioma and venous thrombosis. CMAJ 2004 ; 171: 11.
22. Bahrami A, Luan DT, Jae YR. Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med 2008; 132 (3): 326–48.
23. WHO Classification of Tumors of female reproductive organs, 2014.
24. Whittemore AS, Gong G, John EM et al. Prevalence of BRCA1 mutations carriers among non-Hispanic Whites. Cancer Epidemiol Biomarkers 2004; 13: 2078–83.
25. Piver MS, Baker TR, Jishi MF et al. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer 1993; 71: 582–8.
26. Schorge JO, Muto MG, Lee SJ et al. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 2000; 60: 1361–4.
27. Sridhar K, Doria R, Raub W et al. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992; 70 (12): 2969–79.
28. Van Gelder T, Hoogsteden H, Versnel M et al. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989; 43 (4): 222–7.
29. Abdullaev A.G., Polotskiy B.E., Davydov M.M. The levels of tumor markers for pseudomyxoma and peritoneal mesothelioma. Oncogynecology. 2016; 1: 31–6 (in Russian).
30. Antmann KH, Pomfret EA, Aisner J et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1983; 1 (6): 386–99.
31. Antman K, Shemin R, Ryan L et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988; 6: 147–53.
32. Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32: 676–81.
33. Piccigallo E, Jeffers L, Reddy R et al. Malignant peritoneal mesothelioma. A clinical and laparoscopic study of ten cases. Dig Dis Sci 1988; 33 (5): 633–9.
34. Turner K, Varghese S, Alexander HR Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 2012; 10: (1): 49–57.
35. Langer CJ, Rosenblum N, Hogan M et al. Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: Favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 1993; 32: 204–8.
36. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118 (7): 547–50.
37. Manzini V, Recchia L, Cafferata M et al. Malignant peritoneal mesothelioma: A multicenter study on 81 cases. Ann Oncol 2010; 21 (2): 348–53.
38. Blackham AU, Shen P, Stewart JH et al. Cytoreductive surgery with intraperitoneal chemotherapy for malignant peritoneal mesothelioma: mitomycin vs. cisplatin. Ann Surg Oncol 2010; 17: 2720–7.
39. Yan TD, Deraco M, Baratti D et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. J Clin Oncol 2009; 27 (36): 6237–42.
40. Helm JH, Miura JT, Glenn JA et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis. Ann Surg Oncol 2015; 22 (5): 1686–93. DOI: 10.1245/s10434-014-3978-x
41. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248–59.
42. Tjulandin A.S., Rumyantsev A.A., Morkhov K.Y. et al. Retrospective analysis of long-term survival outcomes of primary cytoreduction and neoadjuvant chemotherapy in patients with ovarian cancer stage IIIC–IV. Malignant Tumours. 2018; 3: 86–94. DOI: 10.18027/2224-5057-2018-8-3-86-94 (In Russian).
43. Gourley C, Walker JL, Mackay HJ. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book 2016; 35: 143–51.
44. Vergote I, Trope CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943–53.
45. Chi DS, Musa F, Dao F et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012; 124: 10–4.
46. Komov D.V., Kolyadina I.V., Polikarpova S.B. et al. Difficulties in the diagnosis of appendix cancer: a clinical report. Russian Journal of Oncology. 2013; 2: 40–2 (in Russian).
47. Kolyadina I.V., Komov D.V., Roshchin E.M. et al. Metastatic lesion of the soft tissues of the anterior abdominal wall (description of the clinical case). Journal of Modern Oncology. 2009; 11 (1): 54–7 (in Russian).
48. Filonenko D.A., Ganshina I.P., Kondratyeva O.E. et al. Characteristics of metastatic lobular breast cancer. Obstetrics and Gynecology. 2019; 10: 180–7 (in Russian). DOI: 10.18565/aig.2019.10.180-187
49. Kolyadina I.V., Abdullaev A.G., Tanishina N.B. et al. Multimodal approach to differential diagnosis of breast cancer metastatic lesions: case report. Malignant Tumours. 2017; 3: 31–6. DOI: 10.18027/2224-5057-2017-3-31-36 (In Russian).
50.Kolyadina I.V., Ganshina I.P., Zhukova L.G. et al. Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case. Journal of Modern Oncology. 2017; 19 (4): 36–8 (In Russian).
2. Park MS, Araujo DM. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol 2009; 21 (4): 327–31. DOI: 10.1097/CCO.0b013e32832c9532
3. Benhammane H, Chbani L, Ousadden A et al. Desmoplastic small round cell tumor of the abdomen: A case report and literature review of therapeutic options. Health 2012; 4 (4): 207–11.
4. Li G, Zhang Z, Ma X et al. Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. PLoS One 2013; 8 (1): E.54233. DOI: 10.1371/journal. pone.0054233
5. Sugarbaker PH. Cytoreduction including total gastrectomy for pseudomyxoma peritonei. Brit J Surg 2002; 89: 208–12.
6. Barnetson RJ, Burnett RA, Downie I et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 2006; 125 (1): 67–76.
7. Deraco M, Santoro N, Carraro O et al. Peritoneal carcinomatosis: feature of dissemination. A review. Tumori 1999; 85: 1–5.
8. Смирнова Г.Ф., Кириченко А.Д., Фетисова Т.И. и др. Редкий случай диссеминированного перитонеального лейомиоматоза. Сиб. онкологический журн. 2010; 1: 85–7.
[Smirnova G.F., Kirichenko A.D., Fetisova T.I. et al. Rare case of disseminated peritoneal leiomyomatosis. Siberian Journal of Oncology. 2010; 1: 85–7 (in Russian).]
9. Japanese Classification of Gastric Carcinoma. 2nd English Edition Gastric Cancer. Gastric Cancer 1998; 1: 10–24.
10. Абдуллаев А.Г. Современная система диагностики и лечения псевдомиксомы и мезотелиомы брюшины. Автореф. дис. … д-ра мед. наук. М., 2016.
[Abdullaev A.G. Modern system of diagnostics and treatment of pseudomyxoma and peritoneal mesothelioma. Authoref. dis. ... d-ra med. nauk. Moscow, 2016 (in Russian).]
11. Mok SC, Schorge JO, Weich WR et al. Peritoneal tumours. In: World Health Organization Classifi cation of tumours. Pathology & genetics of tumours of breast and female genital organs. IARC Press – Lyon, 2003; p. 197–202.
12. Shmueli E, Leider-Trejo L, Schwartz I et al. Primary papillary serous carcinoma of the peritoneum in a man. Ann Oncol 2001; 12: 563–7.
13. Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal and fallopian tube carcinomas in the United States, 1995–2004. Cancer Epidemiol Biomarkers Prev 2009; 18: 132–9.
14. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005; 123 (5): 724–37.
15. Eltabbakh GH, Piver MS. Oncology. 12nd ed. Washington: Williston Park, 1998; p. 813–19.
16. De Panther Manzini V. Malignant peritoneal mesothelioma. Tumori 2005; 91: 1–5.
17. Tejido Garcia R, Anta Fernandez M, Hernandez Hernandez JL et al. Fever of unknown origin as the clinical presentation of malignant peritoneal mesothelioma. Ann Med Interna 1997; 14: 573–5 (in Spanish).
18. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005; 123: 724–37.
19. Le DT, Deavers M, Hunt K et al. Cisplatin and irinotecan (CPT – 11) for peritoneal mesothelioma. Cancer Invest 2003; 21: 682–9.
20. Naka H, Naka A. Clinicopathological study on 100 Japanese patients with peritoneal mesothelioma in Japan. Gan No Rinsho 1984; 30: 1–10.
21. Schneiderman H. Mesothelioma and venous thrombosis. CMAJ 2004 ; 171: 11.
22. Bahrami A, Luan DT, Jae YR. Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med 2008; 132 (3): 326–48.
23. WHO Classification of Tumors of female reproductive organs, 2014.
24. Whittemore AS, Gong G, John EM et al. Prevalence of BRCA1 mutations carriers among non-Hispanic Whites. Cancer Epidemiol Biomarkers 2004; 13: 2078–83.
25. Piver MS, Baker TR, Jishi MF et al. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer 1993; 71: 582–8.
26. Schorge JO, Muto MG, Lee SJ et al. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 2000; 60: 1361–4.
27. Sridhar K, Doria R, Raub W et al. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992; 70 (12): 2969–79.
28. Van Gelder T, Hoogsteden H, Versnel M et al. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989; 43 (4): 222–7.
29. Абдуллаев А.Г., Полоцкий Б.Е., Давыдов М.М. Показатели уровней опухолевых маркеров при псевдомиксоме и мезотелиоме брюшины. Онкогинекология. 2016; 1: 31–6.
[Abdullaev A.G., Polotskiy B.E., Davydov M.M. The levels of tumor markers for pseudomyxoma and peritoneal mesothelioma. Oncogynecology. 2016; 1: 31–6 (in Russian).]
30. Antmann KH, Pomfret EA, Aisner J et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1983; 1 (6): 386–99.
31. Antman K, Shemin R, Ryan L et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988; 6: 147–53.
32. Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32: 676–81.
33. Piccigallo E, Jeffers L, Reddy R et al. Malignant peritoneal mesothelioma. A clinical and laparoscopic study of ten cases. Dig Dis Sci 1988; 33 (5): 633–9.
34. Turner K, Varghese S, Alexander HR Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 2012; 10: (1): 49–57.
35. Langer CJ, Rosenblum N, Hogan M et al. Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: Favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 1993; 32: 204–8.
36. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118 (7): 547–50.
37. Manzini V, Recchia L, Cafferata M et al. Malignant peritoneal mesothelioma: A multicenter study on 81 cases. Ann Oncol 2010; 21 (2): 348–53.
38. Blackham AU, Shen P, Stewart JH et al. Cytoreductive surgery with intraperitoneal chemotherapy for malignant peritoneal mesothelioma: mitomycin vs. cisplatin. Ann Surg Oncol 2010; 17: 2720–7.
39. Yan TD, Deraco M, Baratti D et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. J Clin Oncol 2009; 27 (36): 6237–42.
40. Helm JH, Miura JT, Glenn JA et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis. Ann Surg Oncol 2015; 22 (5): 1686–93. DOI: 10.1245/s10434-014-3978-x
41. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248–59.
42. Тюляндина А.С., Румянцев А.А., Морхов К.Ю. и др. Ретроспективный анализ отдаленных результатов применения первичной циторедукции и предоперационной химиотерапии на первом этапе лечения больных IIIC–IV стадий рака яичника. Злокачественные опухоли. 2018; 8 (3): 86–94. DOI: 10.18027/2224-5057-2018-8-3-86-94
[Tjulandin A.S., Rumyantsev A.A., Morkhov K.Y. et al. Retrospective analysis of long-term survival outcomes of primary cytoreduction and neoadjuvant chemotherapy in patients with ovarian cancer stage IIIC–IV. Malignant Tumours. 2018; 3: 86–94. DOI: 10.18027/2224-5057-2018-8-3-86-94 (In Russian).]
43. Gourley C, Walker JL, Mackay HJ. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book 2016; 35: 143–51.
44. Vergote I, Trope CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943–53.
45. Chi DS, Musa F, Dao F et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012; 124: 10–4.
46. Комов Д.В., Колядина И.В., Поликарпова С.Б. и др. Сложности диагностики рака червеобразного отростка: клиническое наблюдение. Рос. онкологический журн. 2013; 2: 40–2.
[Komov D.V., Kolyadina I.V., Polikarpova S.B. et al. Difficulties in the diagnosis of appendix cancer: a clinical report. Russian Journal of Oncology. 2013; 2: 40–2 (in Russian).]
47. Колядина И.В., Комов Д.В., Рощин Е.М. и др. Метастатическое поражение мягких тканей передней брюшной стенки (описание клинического случая). Современная онкология. 2009; 11 (1): 54–7.
[Kolyadina I.V., Komov D.V., Roshchin E.M. et al. Metastatic lesion of the soft tissues of the anterior abdominal wall (description of the clinical case). Journal of Modern Oncology. 2009; 11 (1): 54–7 (in Russian).]
48. Филоненко Д.А., Ганьшина И.П., Кондратьева О.Е. и др. Особенности метастазирования долькового рака молочной железы. Акушерство и гинекология. 2019; 10: 180–7.
[Filonenko D.A., Ganshina I.P., Kondratyeva O.E. et al. Characteristics of metastatic lobular breast cancer. Obstetrics and Gynecology. 2019; 10: 180–7 (in Russian).]. DOI: 10.18565/aig.2019.10.180-187
49. Колядина И.В., Абдуллаев А.Г., Танишина Н.Б. и др. Мультимодальный подход к дифференциальной диагностике метастатического поражения при раке молочной железы: описание клинического случая. Злокачественные опухоли. 2017; 3: 31–6. DOI: 10.18027/2224-5057-2017-3-31-36
[Kolyadina I.V., Abdullaev A.G., Tanishina N.B. et al. Multimodal approach to differential diagnosis of breast cancer metastatic lesions: case report. Malignant Tumours. 2017; 3: 31–6. DOI: 10.18027/2224-5057-2017-3-31-36 (In Russian).]
50. Колядина И.В., Ганьшина И.П., Жукова Л.Г. и др. Метастатическое поражение мягких тканей ягодичной области при HER2+ раке молочной железы: описание клинического случая. Современная онкология. 2017; 19 (4): 36–8.
[Kolyadina I.V., Ganshina I.P., Zhukova L.G. et al. Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case. Journal of Modern Oncology. 2017; 19 (4): 36–8 (In Russian).]
________________________________________________
2. Park MS, Araujo DM. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol 2009; 21 (4): 327–31. DOI: 10.1097/CCO.0b013e32832c9532
3. Benhammane H, Chbani L, Ousadden A et al. Desmoplastic small round cell tumor of the abdomen: A case report and literature review of therapeutic options. Health 2012; 4 (4): 207–11.
4. Li G, Zhang Z, Ma X et al. Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. PLoS One 2013; 8 (1): E.54233. DOI: 10.1371/journal. pone.0054233
5. Sugarbaker PH. Cytoreduction including total gastrectomy for pseudomyxoma peritonei. Brit J Surg 2002; 89: 208–12.
6. Barnetson RJ, Burnett RA, Downie I et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 2006; 125 (1): 67–76.
7. Deraco M, Santoro N, Carraro O et al. Peritoneal carcinomatosis: feature of dissemination. A review. Tumori 1999; 85: 1–5.
8. Smirnova G.F., Kirichenko A.D., Fetisova T.I. et al. Rare case of disseminated peritoneal leiomyomatosis. Siberian Journal of Oncology. 2010; 1: 85–7 (in Russian).
9. Japanese Classification of Gastric Carcinoma. 2nd English Edition Gastric Cancer. Gastric Cancer 1998; 1: 10–24.
10. Abdullaev A.G. Modern system of diagnostics and treatment of pseudomyxoma and peritoneal mesothelioma. Authoref. dis. ... d-ra med. nauk. Moscow, 2016 (in Russian).
11. Mok SC, Schorge JO, Weich WR et al. Peritoneal tumours. In: World Health Organization Classifi cation of tumours. Pathology & genetics of tumours of breast and female genital organs. IARC Press – Lyon, 2003; p. 197–202.
12. Shmueli E, Leider-Trejo L, Schwartz I et al. Primary papillary serous carcinoma of the peritoneum in a man. Ann Oncol 2001; 12: 563–7.
13. Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal and fallopian tube carcinomas in the United States, 1995–2004. Cancer Epidemiol Biomarkers Prev 2009; 18: 132–9.
14. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005; 123 (5): 724–37.
15. Eltabbakh GH, Piver MS. Oncology. 12nd ed. Washington: Williston Park, 1998; p. 813–19.
16. De Panther Manzini V. Malignant peritoneal mesothelioma. Tumori 2005; 91: 1–5.
17. Tejido Garcia R, Anta Fernandez M, Hernandez Hernandez JL et al. Fever of unknown origin as the clinical presentation of malignant peritoneal mesothelioma. Ann Med Interna 1997; 14: 573–5 (in Spanish).
18. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005; 123: 724–37.
19. Le DT, Deavers M, Hunt K et al. Cisplatin and irinotecan (CPT – 11) for peritoneal mesothelioma. Cancer Invest 2003; 21: 682–9.
20. Naka H, Naka A. Clinicopathological study on 100 Japanese patients with peritoneal mesothelioma in Japan. Gan No Rinsho 1984; 30: 1–10.
21. Schneiderman H. Mesothelioma and venous thrombosis. CMAJ 2004 ; 171: 11.
22. Bahrami A, Luan DT, Jae YR. Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med 2008; 132 (3): 326–48.
23. WHO Classification of Tumors of female reproductive organs, 2014.
24. Whittemore AS, Gong G, John EM et al. Prevalence of BRCA1 mutations carriers among non-Hispanic Whites. Cancer Epidemiol Biomarkers 2004; 13: 2078–83.
25. Piver MS, Baker TR, Jishi MF et al. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer 1993; 71: 582–8.
26. Schorge JO, Muto MG, Lee SJ et al. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 2000; 60: 1361–4.
27. Sridhar K, Doria R, Raub W et al. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992; 70 (12): 2969–79.
28. Van Gelder T, Hoogsteden H, Versnel M et al. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989; 43 (4): 222–7.
29. Abdullaev A.G., Polotskiy B.E., Davydov M.M. The levels of tumor markers for pseudomyxoma and peritoneal mesothelioma. Oncogynecology. 2016; 1: 31–6 (in Russian).
30. Antmann KH, Pomfret EA, Aisner J et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1983; 1 (6): 386–99.
31. Antman K, Shemin R, Ryan L et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988; 6: 147–53.
32. Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32: 676–81.
33. Piccigallo E, Jeffers L, Reddy R et al. Malignant peritoneal mesothelioma. A clinical and laparoscopic study of ten cases. Dig Dis Sci 1988; 33 (5): 633–9.
34. Turner K, Varghese S, Alexander HR Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 2012; 10: (1): 49–57.
35. Langer CJ, Rosenblum N, Hogan M et al. Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: Favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 1993; 32: 204–8.
36. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118 (7): 547–50.
37. Manzini V, Recchia L, Cafferata M et al. Malignant peritoneal mesothelioma: A multicenter study on 81 cases. Ann Oncol 2010; 21 (2): 348–53.
38. Blackham AU, Shen P, Stewart JH et al. Cytoreductive surgery with intraperitoneal chemotherapy for malignant peritoneal mesothelioma: mitomycin vs. cisplatin. Ann Surg Oncol 2010; 17: 2720–7.
39. Yan TD, Deraco M, Baratti D et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. J Clin Oncol 2009; 27 (36): 6237–42.
40. Helm JH, Miura JT, Glenn JA et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis. Ann Surg Oncol 2015; 22 (5): 1686–93. DOI: 10.1245/s10434-014-3978-x
41. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248–59.
42. Tjulandin A.S., Rumyantsev A.A., Morkhov K.Y. et al. Retrospective analysis of long-term survival outcomes of primary cytoreduction and neoadjuvant chemotherapy in patients with ovarian cancer stage IIIC–IV. Malignant Tumours. 2018; 3: 86–94. DOI: 10.18027/2224-5057-2018-8-3-86-94 (In Russian).
43. Gourley C, Walker JL, Mackay HJ. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book 2016; 35: 143–51.
44. Vergote I, Trope CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943–53.
45. Chi DS, Musa F, Dao F et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012; 124: 10–4.
46. Komov D.V., Kolyadina I.V., Polikarpova S.B. et al. Difficulties in the diagnosis of appendix cancer: a clinical report. Russian Journal of Oncology. 2013; 2: 40–2 (in Russian).
47. Kolyadina I.V., Komov D.V., Roshchin E.M. et al. Metastatic lesion of the soft tissues of the anterior abdominal wall (description of the clinical case). Journal of Modern Oncology. 2009; 11 (1): 54–7 (in Russian).
48. Filonenko D.A., Ganshina I.P., Kondratyeva O.E. et al. Characteristics of metastatic lobular breast cancer. Obstetrics and Gynecology. 2019; 10: 180–7 (in Russian). DOI: 10.18565/aig.2019.10.180-187
49. Kolyadina I.V., Abdullaev A.G., Tanishina N.B. et al. Multimodal approach to differential diagnosis of breast cancer metastatic lesions: case report. Malignant Tumours. 2017; 3: 31–6. DOI: 10.18027/2224-5057-2017-3-31-36 (In Russian).
50.Kolyadina I.V., Ganshina I.P., Zhukova L.G. et al. Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case. Journal of Modern Oncology. 2017; 19 (4): 36–8 (In Russian).
Авторы
А.Г. Абдуллаев*, Н.А. Козлов, Н.К. Шахпазян, А.В. Цыганкова
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия
*amirdo@mail.ru
Blokhin National Medical Research Center of Oncology, Moscow, Russia
*amirdo@mail.ru
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия
*amirdo@mail.ru
________________________________________________
Blokhin National Medical Research Center of Oncology, Moscow, Russia
*amirdo@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.